At this time, posts about HanAll Biopharma are rapidly increasing on portals and securities communities. Today, foreign investors have net sold 12,601 shares of HanAll Biopharma, and institutions have net sold 72,000 shares, according to provisional data. HanAll Biopharma is known as an R&D-focused pharmaceutical and bio company.
As of 1:30 PM on the 17th, HanAll Biopharma's stock price is 23,350 KRW, down 3.31% from the previous day, with a trading volume of 862,180 shares, which is 86.11% of the 5-day average trading volume.
In addition to HanAll Biopharma, posts by investors are also rapidly increasing for POSCO International (047050), Ewha Electric (024810), and Dentis (261200).
※Source: AI Investment Assistant AI Rassi
※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
